WO2026015090A1

WO2026015090A1 - Additive anti-cancer composition comprising sesamin and hesperidin

Info

Publication number: WO2026015090A1
Application number: PCT/TH2024/050031
Authority: WO
Inventors: Thanatta CHAIWONGWAT
Original assignee: Emily Thailand Co Ltd
Current assignee: Emily Thailand Co Ltd
Priority date: 2024-07-11
Filing date: 2024-07-11
Publication date: 2026-01-15
Anticipated expiration: 2027-01-11

Abstract

The combination of sesamin and hesperidin provides a promising therapeutic approach for cancer treatment due to its additive effects, enhancing efficacy and potentially reducing side effects compared to conventional therapies.

Description

ADDITIVE ANTI-CANCER COMPOSITION COMPRISING SESAMIN AND HESPERIDIN

FIELD OF THE INVENTION

The present invention relates to a pharmaceutical composition with anti-cancer properties. More specifically, it concerns a synergistic combination of sesamin and hesperidin for use in cancer prevention and treatment.

BACKGROUND OF THE INVENTION

Cancer remains one of the leading causes of mortality worldwide. Current treatments such as chemotherapy and radiation often come with significant side effects. There is a pressing need for effective treatments with fewer side effects. Natural compounds have gained attention due to their potential therapeutic benefits and lower toxicity profiles.

Sesamin, a lignan found in sesame seeds, and hesperidin, a flavonoid found in citrus fruits, have individually demonstrated anti-cancer properties. However, their combined effect on cancer cells has not been extensively explored.

SUMMARY OF THE INVENTION

The present invention provides a pharmaceutical composition comprising sesamin and hesperidin that exhibits a synergistic effect in the inhibition of cancer cell growth. This synergistic combination enhances the efficacy of treatment while potentially reducing side effects compared to conventional therapies.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 Illustration of the inhibition graph of Sesamin on the breast cancer cell line, MDA- MB 231 and showing the IC20 at 152.87 +/- 25.50 M.

Figure 2 Illustration of the inhibition graph of Hesperidin on the breast cancer cell line, MDA-MB 231 and showing the IC20 at 126.57 +/- 5.50 pM.

Figure 3 Illustration of the inhibition graph of sesamin combine with hesperidin at IC20 on the breast cancer cell line, MDA-MB 231

Figure 4 Illustration of the ICio, IC20 and IC50 drug value in MDA-MB231 cells at 24 h

DETAILED DESCRIPTION OF THE INVENTION

Composition The invention relates to a dietary supplement composition comprising:

Sesamin or a pharmaceutically acceptable salt/derivatives thereof.

Hesperidin or a pharmaceutically acceptable salt/derivatives thereof.

The composition can be formulated in various forms, including but not limited to tablets, capsules, powders, and liquid formulations.

Additive Effect

The inventors have discovered that the combination of sesamin and hesperidin exhibits an additive effect in the inhibition of cancer cell growth. The additive effect was demonstrated through in vitro studies on cancer cell lines.

Method of Treatment

The invention also provides a method of treating cancer in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition containing sesamin and hesperidin. The method can be used to treat various types of cancer, including but not limited to breast cancer, prostate cancer, lung cancer, and colon cancer.

Dosage and Administration

The effective dosage of the composition will depend on the type and severity of cancer, the patient’s age, weight, and overall health. However, typical dosages may range from about 0.1 to 500 mg/kg body weight per day, with a preferred range of about 1 to 100 mg/kg body weight per day.

Examples

Example 1: In Vitro Study on Breast Cancer Cells**

Human breast cancer cells (MDA-MB 231) were treated with sesamin and hesperidin individually and in combination. The combination treatment showed a significant reduction in cell viability compared to the individual treatments, indicating an additive effect.

Demonstration of the Response Additivity approach. This model assumes synergistic effects when the drug combination induces a greater response than the sum of the individual drugs’ effects. Based on IC20 sesamin = 126.57+5.50 mM, IC20 hesperidin= 152.87+25.50 mM, sesamin+ IC20 hesperidin IC40 =100.12 +3.57 mM and hesperidin+IC20 sesamin IC40= 150.21+17 mM Adapted from (Foucquier and Guedj, 2015) ***Combine between sesamin and hesperidin is ADDITIVE BEST MODE OF THE INVENTION

As described in DETAILED DESCRIPTION OF THE INVENTION

Claims

1. A pharmaceutical composition comprising sesamin and hesperidin, wherein the composition exhibits a synergistic anti-cancer effect.

2. The pharmaceutical composition according to claim 1, wherein the composition is formulated as a tablet, capsule, powder, or liquid.

3. A method of treating cancer in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.

4. The method according to claim 3, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, and colon cancer.

5. The method according to claim 3, wherein the effective amount ranges from about 0.1 to

500 mg/kg body weight per day.